Product Information

IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB is a generic product labeled by Solco Healthcare US LLC, priced at $0.1928 per EA under NDC 43547033103. Its NADAC has been published 619 times since Aug 20, 2014.

IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB

Irbesartan and Hydrochlorothiazide
$0.1928per EA

Strength

12.5; 300 mg/1; mg/1

NDC

43547033103

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

6/17/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA203072

On Market Since

3/1/2014

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has been published 619 times since Aug 20, 2014, and over the history we have for it it has declined 61.3%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1928 per EA
All-time high$0.4980 (Sep 10, 2014)
All-time low$0.1656 (May 22, 2024)
52-week high$0.2145
52-week low$0.1928
Median price$0.2815
Average price$0.2912
Largest weekly change+34.4% (Jun 19, 2024)
Weeks tracked619
Tracking sinceAug 20, 2014

Price History

1W

0.0%

1M

-1.1%

3M

-3.7%

6M

-9.4%

1Y

-10.1%

3Y

-16.6%

5Y

-40.5%

All

-61.3%

Generic Alternatives

The matcher finds 5 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 5 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, manufactured by Solco Healthcare US LLC, is $0.1928 per EA (NDC 43547033103), effective Jun 24, 2026.

How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB changed over time?

Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has declined 61.3%. It has been tracked across 619 weekly CMS publications since Aug 20, 2014.

What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?

Since Aug 20, 2014, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has ranged from a low of $0.1656 (May 22, 2024) to a high of $0.4980 (Sep 10, 2014), with a median of $0.2815 per EA.

Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?

Yes. 5 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, is $0.1698 per EA — about 12% below IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB.

Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?

IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB (NDC 43547033103) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.